22.8 C
New York
Sunday, June 14, 2026

Tag: developments

newssourceFORcompanyinformationcontent1marketreleases

Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02

DUBAI, United Arab Emirates, June 14, 2026 (GLOBE NEWSWIRE) -- Ruvi AI, the AI-powered blockchain ecosystem combining artificial intelligence, decentralized infrastructure, creator monetization, and tokenized participation, has announced that Phase 3 of its ongoing token presale has now reached 90% completion.

XM Announces Enhanced Trading Conditions and Opportunities for Global Traders – Featuring Partner Code 274PQ

TORONTO, June 14, 2026 (GLOBE NEWSWIRE) -- As participation in online financial markets continues to expand worldwide, trading platforms are increasingly focused on technology, education, and user accessibility. XM, an international online trading platform, has announced ongoing developments across its platform ecosystem while highlighting the availability of Partner Code 274PQ for eligible new users during the registration process.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI

SPCX IPO live: Weiss Ratings' Disruptors & Dominators covers orbital AI supply chain research. 4 bonus reports. Weiss Ratings LLC.

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Federal Signal Provides Update on Streator, Illinois Facility; Announces Signing of Definitive Agreement to Acquire Western Technology, Expanding its Presence in Portable Industrial Signaling...

DOWNERS GROVE, Ill., June 12, 2026 /PRNewswire/ -- Federal Signal Corporation (NYSE: FSS) (the "Company"), a leader in environmental and safety solutions, today provided an...

Lotus Tech Announces Operational and Earnings Reporting Updates

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (Nasdaq: LOT) (“Lotus Tech” or the “Company”), a leading global intelligent and luxury mobility provider, today provided an update on recent developments and announced the temporary suspension of the publication of earnings releases for the first quarter and third quarter of fiscal year 2026.

Bitmine Immersion Technologies Announces Initial Dividends and NYSE Listing for Series A Preferred Stock

Bitmine's Board of Directors declares initial cash dividends on the Company's 9.50% Series A Perpetual Preferred StockSeries A Preferred Stock approved for listing on...

Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs

About Pharma Equity Group A/S

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers